New targeted treatment for ovarian cancer using radiopharmaceuticals
Official title: A novel platform for targeted radiopharmaceuticals for imaging and therapy of ovarian cancer
Funded at Oncurie INC. · NIH-10918937 · Data updated 2026-11-12
This study is testing a new treatment for ovarian cancer that aims to help doctors see the cancer better and treat it more effectively by using a special compound that targets a specific part of the cancer cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncurie INC. NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $349,808 |
| NIH project number | 1R41CA291316-01 |
| Project ID | NIH-10918937 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women diagnosed with ovarian cancer, particularly those with advanced stages of the disease.
✕Less likely to help
Patients with early-stage ovarian cancer or those without folate receptor expression may not benefit from this research.
What this research studies
This research focuses on developing a novel compound that targets ovarian cancer by binding to the folate receptor, which is often overexpressed in ovarian cancer cells. The compound is designed to deliver radionuclides for both imaging and therapy, aiming to improve early detection and treatment outcomes. By utilizing a proprietary moiety, the research seeks to enhance the safety and effectiveness of the treatment, addressing a significant unmet need in ovarian cancer care. Patients may benefit from more precise imaging and targeted therapy options.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic and therapeutic options for women with ovarian cancer.
How similar studies have gone: Previous research has shown promise in using targeted radiopharmaceuticals for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Oncurie INC.
Raleigh, United States Active
Researchers
- Principal investigator: Lapi, Suzanne Elizabeth — Oncurie INC.
- Study coordinator: Lapi, Suzanne Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Understanding the experience of ovarian cancer after diagnosis to improve survivorship
This NIH grant funds a mixed-methods study to better understand physical and emotional challenges faced by ovarian cancer survivors and how supportive care can help them live better after diagnosis.
-
Targeting quiescent ovarian cancer cells to overcome chemotherapy resistance
A study focusing on why some ovarian cancer cells pause dividing and resist chemotherapy, with the goal of finding new treatment targets for relapsed disease.
-
Photodynamic lipids to boost chemotherapy for metastatic ovarian cancer
A patient-friendly approach tests a light-activated method to make ovarian cancer metastases more sensitive to chemotherapy.
-
Integrated framework to validate and quantify proteoforms in patient-derived ovarian cancer cells
A collaboration will combine advanced top-down proteomics with a new computational method to precisely identify and measure intact proteoforms in tiny samples from ovarian cancer cells.
-
Overcoming platinum resistance in ovarian cancer: finding biomarkers and new targets
Researchers are looking for new biomarkers and targets to help prevent or overcome platinum resistance in high‑risk ovarian cancer so patients have better chances at long-term control.
-
Alternative NF-kB activation after chemotherapy in ovarian cancer
This grant studies how ovarian cancer might come back after chemotherapy by looking at specific signaling pathways in cancer cells and the tumor environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.